TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04630899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive joint mobilization
Description: PJM uses Maitland's Mobilization method, grade III (high amplitude in the end range of the joint and 1 second vibration in the middle range through linear motion in which tissue resistance is felt). The participant is in a supine position, and the physical therapist holds the talus with one hand and the tibia with the other hand, and performs joint mobilization in the posterior direction with the hand holding the talus.
Study: NCT06777524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin-to-skin contact education
Description: For the intervention group, additional education on the importance and clinical benefits of mother-infant skin-to-skin contact will be provided (including an educational video). They will be instructed to engage in a minimum of 6 hours of skin-to-skin contact per day with the infant's and mother's chests exposed for at least 15 minutes per session, and to keep a record of the contact time, as well as the time spent holding the clothed infant and a daily feeding diary.
Study: NCT06779136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Every four weeks, subcutaneous injection，Switch to MG-K10 treatment after 24 weeks of administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Every four weeks, subcutaneous injection，Switch to MG-K10 treatment after 24 weeks of administration
Study: NCT04440202

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional sea bream
Description: Participants initially randomized to this intervention arm will be provided with a total of 8 conventional sea bream fillets and will be asked to consume them twice weekly for 1 month. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enriched sea bream
Description: Participants initially randomized to this intervention arm will be provided with a total of 8 enriched sea bream fillets and will be asked to consume them twice weekly for 1 month. Enriched sea bream fillets will be produced by a fish farming company from fish bread with a diet enriched with a fraction of bioactive polar lipids extracted from olive oil by-products. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
Study: NCT05342545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alert-based computerized decision support
Description: For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.
Study: NCT06779136

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Every four weeks, subcutaneous injection，Switch to MG-K10 treatment after 24 weeks of administration
Study: NCT06777888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Healthy Living Program weekly group sessions
Description: Children aged 8-12 and at least one caregiver will meet for 9 weekly virtual group intervention sessions (2 hours per session) with program facilitators and will also have access to a virtual Q and A session and up to 3 virtual cooking classes with a Registered Dietician. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-guided Web Portal Resources Only
Description: Children aged 8-12 and at least one caregiver will be offered access to digital educational content and downloadable resources on topics such as physical activity, healthy eating, and positive mental well-being.
Study: NCT06779318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Tegafur, Gimeracil, and Oteracil Potassium (S-1) 40-60 mg per dose, orally (p.o.), twice daily (BID), from Day 1 to Day 28, with a 6-week cycle, for a total of 8 cycles; or from Day 1 to Day 14, with a 3-week cycle, for a total of 16 cycles.
Study: NCT05657821

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pumpkin seeds extract capsules
Description: the intervention group was given pumpkin seed capsules for 12 weeks, and the intervention group was given iron tablets for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pumpkin seeds extract capsules
Description: the intervention group was given pumpkin seed capsules for 12 weeks, and the intervention group was given iron tablets for 12 weeks
Study: NCT06466616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real stretching
Description: Aplying 3 sesions of ESWT in patients with plantar fasciitis in the zone of pain. Futhermore they are going to do a program of 8 weeks stretching of plantar fascia, gastrocnemius and hamstring muscle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stretching
Description: Aplying 3 sesions of ESWT in patients with plantar fasciitis in the zone of pain. Futhermore they are going to do a program of 8 weeks placebo stretching of plantar fascia, gastrocnemius and hamstring muscle.
Study: NCT06336590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning Exercise
Description: Exercise is changed from normal (6pm-11pm) exercise to morning (6am-11am) exercise.
Study: NCT05986565

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Families Moving Forward (FMF) Teacher adapted training
Description: The FMF Connect Teacher Companion website is designed to offer teachers evidence-based education about FASD and strategies to support students with FASD. It is adapted from the FMF Program and FMF Connect, evidence based interventions to support caregivers of children with FASD. The FMF Program and FMF Connect aim to improve caregivers' efficacy and satisfaction as a parent, efficacy, attributions for their child's behavior, and the parent-child relationship.
Study: NCT06055946

Intervention type: DEVICE
Intervention: robotic assisted radical prostatectomy
Description: Adult male patients undergoing elective robotic assisted radical prostatectomy.will be included in the study
Study: NCT05991284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril-valsartan
Description: sacubitril-valsartan (target dose 97/103 mg twice daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: including SGLT-2 inhibitor and MRA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: including SGLT-2 inhibitor and MRA
Study: NCT06402123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zagociguat 15mg
Description: Once-daily oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zagociguat 15mg
Description: Once-daily oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zagociguat 30mg
Description: Once-daily oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zagociguat 30mg
Description: Once-daily oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once-daily oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once-daily oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once-daily oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once-daily oral tablets
Study: NCT05253833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 Dose 1
Description: Solid Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 Dose 1
Description: Solid Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 Dose 2
Description: Solid Oral Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol Tablet
Description: Solid tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol Tablet
Description: Solid tablet
Study: NCT06376045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Rocatinlimab will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Rocatinlimab will be administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Rocatinlimab will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by SC injection.
Study: NCT05413018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04534205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT113
Description: IV injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT113
Description: IV injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT05074420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Given Orally
Study: NCT06285474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Focused Ultrasound Pulsation (LIFUP)
Description: All participants will undergo 3 identical LIFUP sessions. All sessions must occur at least 1 day apart, and no more than 3 days apart, such that sessions may occur at minimum on days 1, 3, 5 and at maximum may occur on days 1, 5, 9.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low Intensity Focused Ultrasound Pulsation (LIFUP)
Description: All participants will undergo 3 identical LIFUP sessions. All sessions must occur at least 1 day apart, and no more than 3 days apart, such that sessions may occur at minimum on days 1, 3, 5 and at maximum may occur on days 1, 5, 9.
Study: NCT05534191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental, comparator and control
Description: To quantify the effect of a strength intervention for footballers on improved range of motion, balance, speed, jump height, and technical football skills compared to a training group performing basic power exercises and machine-based strength training and a control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental, comparator and control
Description: To quantify the effect of a strength intervention for footballers on improved range of motion, balance, speed, jump height, and technical football skills compared to a training group performing basic power exercises and machine-based strength training and a control group.
Study: NCT06158789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR guided low intensity focused ultrasound
Description: Low intensity focused ultrasound opens the blood brain barrier
Study: NCT04728360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2206
Description: 45 mg/0.5 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara (EU-sourced)
Description: 45 mg/0.5 mL
Study: NCT03606967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT04715854

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mask
Description: addition of the mask above the nasal cannulas

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mask
Description: addition of the mask above the nasal cannulas

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mask
Description: addition of the mask above the nasal cannulas
Study: NCT03606967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study: NCT06121375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCA
Description: OCA will be administered.
Study: NCT05359081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856 50 mg or 75 mg, flexibly dosed once daily tablet for 52 weeks
Study: NCT05072223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: A new nerve block guided by ultrasound that aims to block articular branches of the shoulder.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: A common and rapid-onset nerve block method guided by ultrasound for pain control of patients undergoing shoulder surgery.
Study: NCT06121375

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo will be administered.
Study: NCT06534957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online mindfulness-based stress reduction
Description: The online MBSR intervention sessions will be available in a website created specifically for this purpose, where each pre-recorded session will be uploaded so that each patient can begin the intervention at the same time as their chemotherapy regimen. Each session will last approximately 1 hour, for a total of 6 sessions. The topics that will be covered in these sessions include: mindfulness overview, stress and suffering, emotional regulation, meditation, management of stressful situations, self-compassion and acceptance. Participants will watch 1 session per week following the order that will be indicated on the website; patients will be encouraged to watch the sessions during their chemotherapy infusions. During these sessions, patients will be instructed in mindfulness practice and will perform targeted exercises to promote complete consciousness, including mindful body awareness (body scan), gentle yoga exercises, and meditation.
Study: NCT06073912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open sinus lifting
Description: Sinus lateral window to graft the floor of the sinus using sinus red diamond stone
Study: NCT05357911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-106, digoxin
Description: Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin
Study: NCT06073912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open sinus lifting
Description: Sinus lateral window to graft the floor of the sinus using sinus red diamond stone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collecting blood sample
Description: Blood sample is collected to harvest PRP and PRF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collecting blood sample
Description: Blood sample is collected to harvest PRP and PRF
Study: NCT03606967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized Synthetic Long Peptide Vaccine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given SC
Study: NCT06073912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone graft harvesting
Description: Bone graft harvesting from the chin area

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone graft harvesting
Description: Bone graft harvesting from the chin area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenous corticocancellous block graft
Description: Simultaneous implant placement with sinus lifting and grafting using autogenous corticocancellous block, stabilized inside the sinus using clamp or screws that will be removed before closure
Study: NCT03606967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sacituzumab Govitecan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Given IV
Study: NCT05337943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Weekly sessions with a therapist to improve sleep for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: Daily light therapy for 30 minutes for 8 weeks.
Study: NCT02522611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to reduce pain within the targeted zone.
Study: NCT06366425

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample then fibroscan
Description: The patient takes a blood test if none less than 6 months old is available, including a complete blood count (CBC) and a hepatic check. The FIB-4 score will be calculated from this blood test.~If the result of the FIB-4 test is greater than 1.3 the person will be contacted by the SELHV (Service Expert de Lutte contre les Hépatites Virales) of the University Hospital of Montpellier in order to schedule, if she wishes, a second non-invasive screening examination of liver fibrosis by Fibroscan.
Study: NCT05931289

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Crisis Response Planning (ECRP)
Description: Using supportive listening, a therapist conducts a brief interview to gather information about lifetime suicide attempt history and recent SI. The therapist then works with the client to identify a) warning signs for being in crisis, b) self-management/distraction strategies, c) reasons for living, d) sources of social support the client could contact in the event of a crisis, and e) crisis resources (e.g., veterans crisis line, contact information for current providers and local emergency resources). Steps for each of these, as well as specific contacts for social support and professional services are written on an index card provided to the patient and the patient is encouraged to keep the card in an accessible place (e.g., wallet) so it can be utilized in the event of a crisis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)
Description: This weekly, 12-session intervention involves completion of an enhanced crisis response plan, as well as emotion regulation skills training, learning strategies to identify and challenge thinking patterns that contribute to suicide risk, and increased engagement in personally meaningful activities.
Study: NCT05914311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture
Description: secures SCS trial leads with a suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: secures SCS trial leads with a suture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabond
Description: secures SCS trial leads with dermabond